Tumor genotype-specific growth inhibition in vivo by antisense oligonucleotides against a polymorphic site of the large subunit of human RNA polymerase II

Cancer Research

Volumn 62, Issue 7, 2002, Pages 2024-2028

  Fluiter, Kees ^a   Ten Asbroek, Anneloor L M A ^a   Van Groenigen, Marjon ^a   Nooij, Marleen ^a   Aalders, Maurice C G ^a   Baas, Frank ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; PHOSPHOROTHIOIC ACID; PROTEIN P53; RNA POLYMERASE II;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER GROWTH; CELL SURVIVAL; CONTROLLED STUDY; GENETIC POLYMORPHISM; GENOTYPE; GROWTH INHIBITION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE H RAS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ALLELES; ANIMALS; BASE PAIR MISMATCH; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MICE; OLIGONUCLEOTIDES, ANTISENSE; PANCREATIC NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RNA POLYMERASE II; THIONUCLEOTIDES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036532142     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Genetic instabilities in human cancers
2. Genetic variation in mRNA coding sequences of highly conserved genes
3. Selective killing of cancer cells based on loss of heterozygosity and normal variation in the human genome: A new paradigm for anticancer drug therapy
4. Polymorphisms in the large subunit of human RNA polymerase II as target for allele-specific inhibition
5. Specific inhibition of nuclear RNA polymerase II by α-amanitin
6. In vivo degradation of RNA polymerase II largest subunit triggered by a-amanitin
7. The gene encoding the large subunit of human RNA polymerase II is located on the short arm of chromosome 17
8. Tumor-suppressor p53: Implications for tumor development and prognosis
9. Selective Inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides
10. Tritium labeling of antisense oligonucleotides by exchange with tritiated water
11. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity
12. In vivo fate of phosphorothioate antisense oligodeoxynucleotides: Predominant uptake by scavenger receptors on endothelial liver cells
13. Widespread skeletal metastatic potential of human lung cancer revealed by green fluorescent protein expression
14. High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein
15. Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases
16. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides
17. Comparative pharmacokinetics, tissue distribution, and tumor accumulation of phosphorothioate, phosphorodithioate, and methylphosphonate oligonucleotides in nude mice
18. Antisense oligonucleotides as therapeutic agents
19. Single-nucleotide polymorphisms can cause different structural folds of mRNA
20. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids
21. Mixed-backbone oligonucleotides as second-generation antisense agents with reduced phosphorothioate-related side effects